Tivic Health Reports White House Briefing and FDA Meetings Secured Positive Interest in Potential Military and Defense Applications of Its Product Candidates
- FREMONT, Calif.--(BUSINESS WIRE)--Tivic Health® Systems, Inc. (Nasdaq: TIVC), a diversified therapeutics company, announced today that it provided briefings to senior leadership at the White House and FDA which garnered significant positive interest in potential military and defense applications for its biologic and bioelectronic product candidates. Both meetings were held in Washington, D.C. on April 17th. The U.S. Government, through agencies including BARDA, NASA, Defense Threats Reduction A.
- 04/22/2025
|
Tivic Health Extends its Worldwide License of TLR5 Agonist Entolimod to Include the Treatment of Neutropenia
- FREMONT, Calif.--(BUSINESS WIRE)--Tivic Health Systems, Inc. (Nasdaq: TIVC), a diversified therapeutics company, today announced that, on March 28, 2025, it exercised its licensing option for the exclusive, worldwide rights to advance Entolimod™ for a second indication, Neutropenia. This expansion of commercial rights is part of the license agreement with Statera Biopharma for its late-stage Toll-like Receptor 5 (TLR5) immunotherapy program Entolimod™. Neutropenia is a condition characterized b.
- 04/15/2025
|
Tivic Health Systems, Inc. Regains Compliance with NASDAQ Minimum Bid Price Listing Rule
- FREMONT, Calif.--(BUSINESS WIRE)--Tivic Health® Systems, Inc. (Nasdaq: TIVC), a diversified therapeutics company, announced today that it has received confirmation from Nasdaq that the Company has regained compliance with the minimum bid requirements of Nasdaq Listing Rule 5550(a)(2). Consequently, Tivic Health's common stock will continue to be listed and traded on the Nasdaq Capital Market under the symbol “TIVC.” About Tivic Health Systems, Inc. Tivic Health is a diversified therapeutics com.
- 04/10/2025
|
Tivic Health Systems, Inc. (TIVC) Q4 2024 Earnings Call Transcript
- Tivic Health Systems, Inc. (NASDAQ:TIVC ) Q4 2024 Results Conference Call March 21, 2025 4:30 PM ET Company Participants Jennifer Ernst - Chief Executive Officer Lisa Wolf - Interim Chief Financial Officer Operator Welcome to Tivic Health Systems Year-End 2024 Financial Results and Operational Update Conference Call. This call has been prerecorded and the questions you have submitted in advance will be answered following prepared remarks.
- 03/21/2025
|
Tivic Reports Year End 2024 Financial Results and Provides Overview of Strategy for Transformation and Growth
- FREMONT, Calif.--(BUSINESS WIRE)--Tivic Health® Systems, Inc. (Nasdaq: TIVC), a diversified therapeutics company, today announced year end December 31, 2024 financial results, highlighted key developments in its clinical program expansion and discussed progress made across the company's operations. “The important strategic events of the past several months have been nothing short of transformative,” stated Tivic Health Chief Executive Officer, Jennifer Ernst. “We have successfully reshaped the.
- 03/21/2025
|
Tivic Health to Report 2024 Year-End Financial Results on March 21st Via Conference Call and Webcast
- FREMONT, Calif.--(BUSINESS WIRE)--Tivic Health® Systems, Inc. (“Tivic Health”, Nasdaq: TIVC), a diversified therapeutics company harnessing the power of the immune and autonomic nervous systems to fight disease and restore health, today announced that it will report its year-end financial results for 2024 via pre-recorded conference call and webcast on Friday, March 21, 2025 at 1:30 PM PT / 4:30 PM ET. Teleconference Details: Toll Free: 1-877-407-0779 International: 1-201-389-0914 Conference ID.
- 03/13/2025
|
Tivic Health and Feinstein Institute Present New Data Showing Personalized Vagus Nerve Stimulation Method Optimizes Impact on Autonomic Nervous System
- FREMONT, Calif.--(BUSINESS WIRE)--Tivic Health® Systems, Inc. (Nasdaq: TIVC), a diversified therapeutics company, announced today new data that shows personalizing its non-invasive vagus nerve stimulation (ncVNS) method optimized the stimulation's impact on autonomic nervous system activity. Tivic Health believes these findings strongly support its strategy to develop highly personalized neuromodulation devices that can better address inflammatory, cardiac and neurologic disorders compared to c.
- 03/06/2025
|
Tivic Health Systems, Inc. Announces Reverse Stock Split
- FREMONT, Calif.--(BUSINESS WIRE)--Tivic Health® Systems, Inc. (Nasdaq: TIVC) (“Tivic Health” or the “Company), a diversified therapeutics company, announced today that its Board of Directors has declared a 1-for-17 reverse stock split of the Company's issued and outstanding shares of common stock. The purpose of the reverse stock split is to bring the Company into compliance with the minimum bid price requirement for continued listing on the Nasdaq Capital Market (“Nasdaq”), and is part of the.
- 03/05/2025
|
Tivic Health Files Patent For Optimized Electrical Stimulation of the Vagus Nerve
- FREMONT, Calif.--(BUSINESS WIRE)--Tivic Health® Systems, Inc. (Nasdaq: TIVC), a diversified therapeutics company harnessing the power of the immune and autonomic nervous systems to fight disease and restore health, announced today that it has filed a new patent application with the U.S. Patent Office. Patent No. 63,492,402, entitled “Method and Apparatus for Electrical Stimulation of the Vagus Nerve,” expands the claims and protection around the technology in advance of potential U.S. Food &.
- 03/03/2025
|
Tivic Health Acquires Exclusive Worldwide Rights to Phase III TLR5 Agonist from Statera Biopharma
- FREMONT, Calif.--(BUSINESS WIRE)--Tivic Health Systems, Inc., (Nasdaq: TIVC) today announced it has acquired worldwide exclusive license rights from Statera Biopharma (OTC: STAB) to the late-stage Toll-like Receptor 5 (TLR5) agonist Entolimod™ for the treatment of acute radiation syndrome (ARS). In addition, the company has acquired an exclusive option to license five additional indications and clinical use cases for Entolimod and its derivative, Entalasta™. This broad licensing agreement estab.
- 02/12/2025
|
CEO Letter to Shareholders Issued by Tivic Health
- FREMONT, Calif.--(BUSINESS WIRE)--Tivic Health® Systems, Inc. (Nasdaq: TIVC), a health tech company developing and commercializing bioelectronic medicine, today released its annual CEO letter to shareholders. Dear Fellow Shareholders: As we conclude 2024 and look forward to 2025, I'd like to take this opportunity to recap some of the important developments this year and share some of our expectations for 2025. Improvements in Commercial Business: We launched ClearUP 2.0, resulting in improved c.
- 12/23/2024
|
Tivic Reports Third Quarter 2024 Financial Results and Provides Business Update
- FREMONT, Calif.--(BUSINESS WIRE)--Tivic Health® Systems, Inc. (Nasdaq: TIVC), a health tech company that develops and commercializes bioelectronic medicine, today announced third quarter and nine-months ended September, 30, 2024 financial results and discussed growth strategies based on its novel, patent-pending vagus nerve stimulation (VNS) science and device technology. “This quarter we made significant progress on each of the three prongs of our strategy for delivering shareholder value," st.
- 11/14/2024
|
Tivic Health Systems, Inc. (TIVC) Q3 2024 Earnings Call Transcript
- Tivic Health Systems, Inc. (NASDAQ:TIVC ) Q3 2024 Earnings Conference Call November 14, 2024 4:30 PM ET Company Participants Jennifer Ernst - Chief Executive Officer Operator Welcome to Tivic Health Systems' Third Quarter 2024 Financial Results and Operational Update Conference Call. This call has been pre-recorded and questions you have submitted in advance will be answered following the prepared remarks.
- 11/14/2024
|
Enrollment Complete in Tivic Health Optimization Study for its Non-Invasive Vagus Nerve Stimulation Device
- FREMONT, Calif.--(BUSINESS WIRE)--Tivic Health® Systems, Inc. (Nasdaq: TIVC), a health tech company developing and commercializing bioelectronic medicine, announced today that full enrollment has been completed in the optimization study for Tivic Health's patent pending, non-invasive vagus nerve stimulation (VNS) device. The study is being conducted by The Feinstein Institute of Bioelectronic Medicine. The objective of the study is to identify device parameters that optimally influence autonomi.
- 11/14/2024
|
Tivic Health Systems, Inc. to Report Third Quarter 2024 Financial Results on November 14
- FREMONT, Calif.--(BUSINESS WIRE)--Tivic Health® Systems, Inc. (Nasdaq: TIVC), a health tech company that develops and commercializes bioelectronic medicine, today announced it will report financial results on Thursday, November 14 after market close. The release will be followed by a pre-recorded conference call and webcast at 1:30 p.m. PST / 4:30 p.m. EST. Shareholders, interested parties, and prospective investors are invited to join via dial in or webcast. The company invites questions to be.
- 11/07/2024
|
Tivic Health CEO Jennifer Ernst to Present at New York BioFuture 2024
- SAN FRANCISCO--(BUSINESS WIRE)--Tivic Health® Systems, Inc. (Nasdaq: TIVC), a health tech company developing and commercializing bioelectronic medicine, announced today that CEO Jennifer Ernst will presenting at the upcoming BioFuture 2024 Conference in New York, October 28-30. Ms. Ernst's presentation, Tuesday, October 29 at 2:30 p.m. EDT, will focus on the company's advances in bioelectronic medicine, including its recently released data on a new approach to vagus nerve stimulation. “This yea.
- 10/24/2024
|
Tivic Health Accelerates VNS Commercial Strategy Development
- SAN FRANCISCO--(BUSINESS WIRE)--Tivic Health® Systems, Inc. (“Tivic Health”, Nasdaq: TIVC), a health tech company that develops and commercializes bioelectronic medicine, today announced it has partnered with Fletcher Spaght (“FSI”), a leading healthcare growth strategy firm, to accelerate development of its commercial strategy for non-invasive cervical vagus nerve stimulation (“ncVNS”). Polaris Market Research estimates the global vagus nerve stimulation market will grow from $8.59 billion in.
- 09/17/2024
|
Tivic Health Systems, Inc. (TIVC) Q2 2024 Earnings Call Transcript
- Tivic Health Systems, Inc. (NASDAQ:TIVC ) Q2 2024 Earnings Conference Call August 14, 2024 4:30 PM ET Company Participants Jennifer Ernst - Chief Executive Officer Kimberly Bambach - Interim Chief Financial Officer Blake Gurfein - Chief Scientific Officer Operator Welcome to the Tivic Health Systems' Second Quarter 2024 Financial Results and Shareholder Update Conference Call. All participants will be in listen-only mode.
- 08/15/2024
|
Tivic Reports Second Quarter 2024 Financial Results
- SAN FRANCISCO--(BUSINESS WIRE)--Tivic Health® Systems, Inc. (“Tivic”, Nasdaq: TIVC), a health tech company that develops and commercializes bioelectronic medicine, today announced its second quarter 2024 financial results and discussed growth strategies based on its investments in vagus nerve stimulation ("VNS"). “This quarter is the start of a potentially transformational period for Tivic. We announced the results of our successful Phase 1 trial of a new approach to non-invasive vagus nerve st.
- 08/14/2024
|
Tivic Health to Report Q2 2024 Financial Results and Corporate Update on August 14th Via Conference Call and Webcast
- SAN FRANCISCO--(BUSINESS WIRE)--Tivic Health® Systems, Inc. (“Tivic Health”, Nasdaq: TIVC), a health tech company that develops and commercializes bioelectronic medicine, today announced that it will report its Q2 2024 financial results and a corporate update via pre-recorded conference call and webcast on Wednesday, August 14 at 1:30 PM PT / 4:30 PM ET. Current shareholders, interested individuals and future investors are encouraged to join the webcast to hear the company executives provide a.
- 08/06/2024
|
Tivic Health Systems (TIVC) Stock Pops Another 39%
- Tivic Health Systems (NASDAQ: TIVC ) stock is on the rise Monday as the company's shares have been volatile the last few days of trading. Initially, shares of TIVC stock were pushed higher by a patent update.
- 07/29/2024
|
Why Is Tivic Health Systems (TIVC) Stock Up 44% Today?
- Tivic Health Systems (NASDAQ: TIVC ) stock is rising higher on Thursday after the bioelectronic medicine company updated its intellectual property portfolio. According to Tivic Health Systems, it has received two new patents that better protect its intellectual properties.
- 07/25/2024
|
Tivic Health: Christina Valauri Appointed to Board of Directors
- SAN FRANCISCO--(BUSINESS WIRE)--Tivic Health® Systems, Inc. (“Tivic Health”, Nasdaq: TIVC), a health tech company that develops and commercializes bioelectronic medicine, is pleased to welcome Christina Valauri to its board of directors, effective July 1, 2024. Ms. Valauri has served as a strategic advisor to the company since April 2023, and brings over 30-years of experience as a seasoned capital markets professional with extensive analytical and management experience. Ms. Valauri has a prove.
- 06/18/2024
|
ServiceNow debuts as a Leader in P&C Claims Management Systems report by independent research firm
- SANTA CLARA, Calif.--(BUSINESS WIRE)--ServiceNow debuts as a Leader in P&C Claims Management Systems report by independent research firm.
- 06/18/2024
|
Tivic Health Partners with the Feinstein Institutes to Advance its Patent-pending, Non-Invasive Cervical Vagus Nerve Stimulation; Begins Optimization of ncVNS for use in Clinical Indications
- SAN FRANCISCO--(BUSINESS WIRE)--Tivic Health® Systems, Inc. (“Tivic Health”, Nasdaq: TIVC), a health tech company that develops and commercializes bioelectronic medicine, announced today it has initiated the second phase of its clinical work to advance its novel non-invasive cervical vagus nerve stimulation (“ncVNS”). The company has entered into a collaboration agreement with The Feinstein Institutes for Medical Research at Northwell Health to optimize its ncVNS device therapy for use in speci.
- 05/22/2024
|
Tivic Health Systems, Inc. (TIVC) Q1 2024 Earnings Call Transcript
- Tivic Health Systems, Inc. (NASDAQ:TIVC ) Q1 2024 Earnings Conference Call May 15, 2024 4:30 PM ET Company Participants Jennifer Ernst – Chief Executive Officer Kimberly Bambach – Interim Chief Financial Officer Conference Call Participants Operator Welcome to the Tivic Health Systems' First Quarter 2024 Financial Results and Shareholder Update Conference Call. All participants will be in listen-only mode.
- 05/15/2024
|
Tivic Reports First Quarter 2024 Financial Results and Subsequent Events
- SAN FRANCISCO--(BUSINESS WIRE)--Tivic Health® Systems, Inc. (“Tivic”, Nasdaq: TIVC), a health tech company that develops and commercializes bioelectronic medicine, today announced its first quarter 2024 financial results with discussion of subsequent events. "Q1 2024 and the weeks thereafter represent a critical juncture in Tivic's advancement in the bioelectronics field. We increased gross profit and reduced operating loss year-over-year by stabilizing our cost of goods, improving our technolo.
- 05/15/2024
|
Tivic Health to Report Q1 2024 Financial Results and Subsequent Events on May 15th Via Conference Call and Webcast
- SAN FRANCISCO--(BUSINESS WIRE)--Tivic Health® Systems, Inc. (“Tivic Health”, Nasdaq: TIVC), a health tech company that develops and commercializes bioelectronic medicine, today announced that it will report its Q1 2024 financial results via pre-recorded conference call and webcast on Wednesday, May 15th at 1:30 PM PT / 4:30 PM ET. Teleconference Details: Toll Free: 877-545-0523 International: 973-528-0016 Participant Access Code: 464810 Webcast Link https://www.webcaster4.com/Webcast/Page/2865/.
- 05/13/2024
|
Tivic Health Announces Closing of $4.0 Million Public Offering
- SAN FRANCISCO--(BUSINESS WIRE)--Tivic Health® Systems, Inc. ("Tivic", Nasdaq: TIVC), a health tech company that develops and commercializes bioelectronic medicine, today announced the closing of its previously announced public offering of an aggregate of 4,710,000 shares of its common stock, Series A warrants to purchase up to 4,710,000 shares of common stock and Series B warrants to purchase up to 7,065,000 shares of common stock, at a combined public offering price of $0.85 per share and acco.
- 05/13/2024
|
Tivic Health Announces Successful Completion of Non-Invasive Vagus Nerve Stimulation Study (VNS); Demonstrates Clinically Effective Biological Changes in the Autonomic, Cardiac, and Central Nervous Systems
- SAN FRANCISCO--(BUSINESS WIRE)--Tivic Health® Systems, Inc. (“Tivic Health”, Nasdaq: TIVC), a health tech company that develops and commercializes bioelectronic medicine, announced today the final results of their pilot research study with The Feinstein Institutes for Medical Research at Northwell Health. Through this collaboration, Tivic Health has confirmed the effectiveness of its patent-pending non-invasive cervical vagus nerve stimulation (ncVNS) approach, which induces responses in the au.
- 05/08/2024
|
Tivic Health Systems, Inc. (TIVC) Q4 2023 Earnings Call Transcript
- Tivic Health Systems, Inc. (TIVC) Q4 2023 Earnings Call Transcript
- 03/25/2024
|
Tivic Reports Fiscal Year 2023 Financial Results
- SAN FRANCISCO--(BUSINESS WIRE)--Tivic Health® Systems, Inc. (“Tivic”, Nasdaq: TIVC), a health tech company that develops and commercializes bioelectronic medicine, today announced its financial results for the year ending December 31, 2023. Tivic's commercial platform is a handheld design that interfaces non-invasively with the trigeminal, sympathetic, and other facial and cranial nerve structures. This platform is the basis for Tivic's existing product, currently marketed with FDA approval as.
- 03/25/2024
|
Tivic Health to Report 2023 Year-End Financial Results on March 25th Via Conference Call and Webcast
- SAN FRANCISCO--(BUSINESS WIRE)--Tivic Health® Systems, Inc. (“Tivic Health”) (Nasdaq: TIVC), a health tech company that develops and commercializes bioelectronic medicine, today announced that it will report its year-end financial results for 2023 via pre-recorded conference call and webcast on Monday, March 25, 2024 at 1:30 PM PT / 4:30 PM ET. Teleconference Details: Toll Free: 888-506-0062 International: 973-528-0011 Participant Access Code: 434944 Webcast Link https://www.webcaster4.com/Webc.
- 03/19/2024
|
Tivic Enters Exclusive Distribution Agreement with Top 10 Medical Product Distributor for Mass Market Retail
- SAN FRANCISCO--(BUSINESS WIRE)--Tivic Health® Systems, Inc. (“Tivic”, Nasdaq: TIVC), a health tech company that develops and commercializes bioelectronic medicine, announced today that it has entered a limited exclusive distribution agreement with one of the Top 10 Medical Equipment Distributors and Suppliers in the nation. Under the terms of the agreement, the new Distributor will have certain exclusive distribution rights for Tivic Health's ClearUP product for Walmart, Target, eBay and Kroger.
- 01/30/2024
|
Tivic Health Announces Launch of New and Improved ClearUP 2.0
- SAN FRANCISCO--(BUSINESS WIRE)--Tivic Health® Systems, Inc. (“Tivic”) (Nasdaq: TIVC), a commercial-phase health technology company that develops and commercializes bioelectronic medicine, announced today the launch of the second generation of Tivic ClearUP. The new and improved Tivic ClearUP 2.0, now with a new chip for power management for faster charge and longer battery life, is available starting today on TivicHealth.com. ClearUP 2.0 is a clinically proven way to clear congestion and reliev.
- 01/08/2024
|
Tivic Health Systems, Inc. (TIVC) Reports Q3 Loss, Misses Revenue Estimates
- Tivic Health Systems, Inc. (TIVC) came out with a quarterly loss of $1.48 per share versus the Zacks Consensus Estimate of a loss of $7. This compares to loss of $27 per share a year ago.
- 11/14/2023
|
Tivic Reports Third Quarter 2023 Financial Results
- SAN FRANCISCO--(BUSINESS WIRE)--Tivic Health® Systems, Inc. (“Tivic”, Nasdaq: TIVC), a health tech company that develops and commercializes bioelectronic medicine, announced its financial results for the third quarter 2023 ended September 30, 2023 (“Q3 2023”). Third Quarter 2023 Financial Highlights Revenue for Q3 2023 was $282 thousand, compared to $161 thousand for Q2 2023 and $477 thousand in Q3 2022. Gross profit was $108 thousand, compared to $63 thousand in Q3 2022, an increase of 71%. Gr.
- 11/14/2023
|
Why Is Tivic Health (TIVC) Stock Up 63% Today?
- Tivic Health (NASDAQ: TIVC ) stock is taking off on Monday as investors are hopeful about the health technology company's upcoming earnings report. Tivic Health is set to release its earnings report for the third quarter of 2023 after markets close on Tuesday.
- 11/13/2023
|
Why Is Tivic Health Systems (TIVC) Stock Up 112% Today?
- Tivic Health Systems (NASDAQ: TIVC ) stock is rocketing higher on Tuesday despite a lack of news this morning. However, one thing that investors will note is the health technology company's shares seeing heavy trading today.
- 08/29/2023
|
Tivic Health Signs Agreement with AmerisourceBergen for Retail Pharmacy Customers
- SAN FRANCISCO--(BUSINESS WIRE)--Tivic Health® Systems, Inc. (“Tivic”, “Company”, Nasdaq: TIVC), a health tech company that develops and commercializes bioelectronic medicine, today announced that the Company has entered into a non-exclusive agreement with AmerisourceBergen, soon to be Cencora, to make Tivic's products available on AmerisourceBergen's third-party marketplace. Tivic's patented ClearUP bioelectronic sinus pain relief device will be offered on AmerisourceBergen Marketplace, the com.
- 08/28/2023
|
Tivic Health Systems, Inc. Announces Reverse Stock Split
- SAN FRANCISCO--(BUSINESS WIRE)--Tivic Health® Systems, Inc. (“Tivic”) (Nasdaq: TIVC) (“Tivic” or the “Company), a commercial-phase health technology company that develops and commercializes bioelectronic medicine, announced today that its Board of Directors has declared a 1-for-100 reverse stock split of the company's issued and outstanding shares of common stock. The reverse stock split will become effective on August 23, 2023 (the “Effective Date”) at 12:01 AM Eastern Time. The company's comm.
- 08/22/2023
|
Why Is Tivic Health Systems (TIVC) Stock Up 45% Today?
- Tivic Health Systems (NASDAQ: TIVC ) stock is rocketing higher on Thursday after getting started on a new clinical trial. According to a press release from the company, its study at The Feinstein Institutes for Medical Research has been given approval by the Institutional Review Board.
- 08/17/2023
|
Tivic Health Funded Study Begins Enrollment for Novel Non-Invasive Bioelectronic Approach to Vagus Nerve Stimulation
- SAN FRANCISCO--(BUSINESS WIRE)--Tivic Health® Systems, Inc. (“Tivic”, Nasdaq: TIVC), a health tech company that develops and commercializes bioelectronic medicine, announced today that the research study that the company is funding at The Feinstein Institutes for Medical Research has received study approval from the Institutional Review Board (“IRB”) and has initiated study recruitment and enrollment for its novel non-invasive bioelectronic device approach to vagus nerve stimulation. An IRB is.
- 08/16/2023
|
Tivic Reports Second Quarter 2023 Financial Results
- SAN FRANCISCO--(BUSINESS WIRE)--Tivic Health® Systems, Inc. (“Tivic”, Nasdaq: TIVC), a health tech company that develops and commercializes bioelectronic medicine, announced its financial results for the second quarter of 2023 ended June 30, 2023 (“Q2 2023”). Second Quarter 2023 Financial Summary Gross profit of 37.5% in the second quarter of 2023, compared to 23.4% in the second quarter of 2022, on total revenue of $60 thousand in the second quarter of 2023 from $123 thousand in the second qua.
- 08/14/2023
|
Tivic Health Reports Second Quarter 2023 Financial Results on August 14th Via Conference Call and Webcast
- SAN FRANCISCO--(BUSINESS WIRE)--Tivic Health® Systems, Inc. (“Tivic Health”, Nasdaq: TIVC), a health tech company that develops and commercializes bioelectronic medicine, today announced that it will report financial results for the first quarter of 2023 via pre-recorded conference call and webcast on Monday, August 14th, 2023 at 1:30 pm PT / 4:30 pm ET. Teleconference Details: Toll-Free: 877-545-0523 International: 973-528-0016 Participant Access Code: 679005 Webcast Link https://www.webcaster.
- 08/07/2023
|
Why Is Tivic Health Systems (TIVC) Stock Down 44% Today?
- Tivic Health Systems (NASDAQ: TIVC ) stock is falling hard on Monday after the health technology company priced a public share offering. According to a press release, the company is offering up 33,173,000 shares of TIVC stock for a price of $0.041 per share.
- 08/07/2023
|
Trading Penny Stocks With Limited Capital: 3 Tops Tips
- The allure of penny stocks is undeniable. Their low price and potential for massive returns create an inviting landscape for individuals, especially those with limited capital, to take a leap into the world of investing.
- 06/28/2023
|
Why Is Tivic Health Systems (TIVC) Stock Down 28% Today?
- Tivic Health Systems (NASDAQ: TIVC ) stock is sliding lower on Tuesday after the company released its earnings report for the first quarter of 2023. That report starts with Tivic Health Systems revealing earnings per share of -11 cents in Q1.
- 05/16/2023
|
Tivic Health Systems, Inc. (TIVC) Reports Q1 Loss, Lags Revenue Estimates
- Tivic Health Systems, Inc. (TIVC) came out with a quarterly loss of $0.11 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.23 per share a year ago.
- 05/15/2023
|
Sector Analysis With Penny Stocks: 3 Top Tips
- Use these tips to analyze sectors to find penny stocks to buy The post Sector Analysis With Penny Stocks: 3 Top Tips appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 05/15/2023
|
Best Penny Stocks To Buy Now? 7 Under $1 To Watch
- Penny stocks under $1 to watch before next week. The post Best Penny Stocks To Buy Now?
- 05/12/2023
|
How to Use Social Media to Make Money Trading Penny Stocks
- Use these tips to utilize social media for trading penny stocks The post How to Use Social Media to Make Money Trading Penny Stocks appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 05/12/2023
|
Tivic Health To Report First Quarter 2023 Financial Results on May 15th Via Conference Call and Webcast
- SAN FRANCISCO--(BUSINESS WIRE)--Tivic Health® Systems, Inc. (“Tivic Health”, Nasdaq: TIVC), a health tech company that develops and commercializes bioelectronic medicine, today announced that it will report financial results for the first quarter 2023 via a pre-recorded conference call and webcast on Monday, May 15th, 2023 at 1:30 pm PT / 4:30 pm ET. Teleconference Details: Toll Free: 877-545-0523 International: 973-528-0016 Participant Access Code: 888610 Webcast Link https://www.webcaster4.co.
- 05/11/2023
|
Why Is Tivic Health Systems (TIVC) Stock Down 51% Today
- Tivic Health Systems (NASDAQ: TIVC ) stock is falling on Thursday after revealing pricing for a public stock offering. The company has priced shares of TIVC stock at 25 cents each.
- 02/09/2023
|
Tivic Health to Report Third Quarter 2022 Financial Results on Monday, November 14th
- SAN FRANCISCO--(BUSINESS WIRE)---- $TIVC #healthcare--Tivic Health® Systems, Inc. (Nasdaq: TIVC), a commercial-phase health technology company that develops and commercializes bioelectronic medicine, today announced that it will report financial results for the third quarter of 2022 via conference call and webcast on Monday, November 14, 2022, at 1:30 PM PT / 4:30 PM ET.
- 11/07/2022
|
Tivic Health to Report 2021 Fourth Quarter & Year-End Shareholder Update on Tuesday, April 19
- SAN FRANCISCO--(BUSINESS WIRE)--Tivic Health® Systems, Inc., (Nasdaq: TIVC) (“Tivic Health” or the “Company”) a commercial-phase health technology company that develops and commercializes bioelectronic medicine, today announced that financial results for the fourth quarter of 2021 and the year-end shareholder update will take place via conference call on Tuesday, April 19, 2022, at 2:00 pm PT / 5:00 pm ET. Conference Call Information: April 19, 2022 at 2:00 pm PT / 5:00 pm ET Teleconference Tol
- 04/14/2022
|
4 Top Penny Stocks To Watch With The Stock Market Down Today
- The stock market is down today but these penny stocks are rallying. The post 4 Top Penny Stocks To Watch With The Stock Market Down Today appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 12/13/2021
|
3 Low Float Penny Stocks To Watch After ENSC Stock Soared
- 3 penny stocks with low floats to watch as shares of ENSC stock skyrocket. The post 3 Low Float Penny Stocks To Watch After ENSC Stock Soared appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 12/07/2021
|
Best Penny Stocks To Buy Now? 5 To Watch Before Next Week
- Are these on your list of penny stocks right now? The post Best Penny Stocks To Buy Now?
- 11/23/2021
|
